经皮冠状动脉介入治疗对心力衰竭患者结局的影响：JACC 最新观点述评。
Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review.
机构信息
Department of Medicine, Stony Brook Renaissance School of Medicine, Stony Brook, New York, USA.
Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
J Am Coll Cardiol. 2021 May 18;77(19):2432-2447. doi: 10.1016/j.jacc.2021.03.310.
Coronary artery disease (CAD) is highly prevalent in patients with heart failure (HF) and accounts for nearly two-thirds of cases. The use of percutaneous coronary intervention (PCI) in HF patients with CAD has markedly increased and has been suggested to be associated with improved outcomes in numerous observational studies. Randomized data comparing the impact of PCI with that of coronary artery bypass graft (CABG) or contemporary guideline-directed medical therapy alone on clinical outcomes and myocardial recovery in patients with HF are lacking. The purpose of this review is to describe the available evidence regarding the impact of PCI in acute HF (in the presence and absence of an acute coronary syndrome), chronic HF with reduced ejection fraction, and HF with preserved ejection fraction. Adequately-powered randomized clinical trials examining the outcomes with PCI in these distinct HF populations are warranted.
冠心病（CAD）在心力衰竭（HF）患者中非常普遍，占病例的近三分之二。经皮冠状动脉介入治疗（PCI）在 CAD 合并 HF 患者中的应用显著增加，并在许多观察性研究中表明与改善结局相关。比较 PCI 与冠状动脉旁路移植术（CABG）或当代指南指导的单纯药物治疗对 HF 患者临床结局和心肌恢复影响的随机数据尚缺乏。本综述的目的是描述关于 PCI 在急性 HF（急性冠状动脉综合征存在和不存在的情况下）、射血分数降低的慢性 HF 和射血分数保留的 HF 中的影响的现有证据。需要进行充分的随机临床试验来检验 PCI 在这些不同 HF 人群中的结局。
Zotero 插件